D yspepsia is a very common symptom, accounting for between 1.2% and 4% of all consultations in primary care in the UK. 1 The management of dyspepsia is estimated to cost the UK more than £1 billion annually. 2 The most recent NICE guidance on dyspepsia was published in 2014. This article serves as a review of dyspepsia with a focus on new approaches to dyspepsia management.
What is dyspepsia?
The term 'dyspepsia' encompasses a variety of symptoms and presentations. These include epigastric discomfort, bloating, early satiety, belching, nausea and heartburn. The Rome IV committee (an organisation striving to improve understanding of functional gastrointestinal disorders) updated their criteria on functional dyspepsia in 2016. 3 The new criteria define dyspepsia as one or more of the following four symptoms for three months within the initial six months of symptom onset: • Bothersome postprandial fullness • Bothersome early satiation • Bothersome epigastric pain • Bothersome epigastric burning.
These symptoms overlap with those arising from other gastrointestinal conditions, including peptic ulcer disease, gastrooesophageal reflux disease (GORD) and functional disorders such as irritable bowel syndrome (IBS). The prevalence of GORD and IBS is also higher in patients with dyspepsia. 2 Despite the non-specific nature of symptoms, dyspepsia is associated with poor health-related quality of life and greater psychological distress. Diagnosing conditions that cause dyspepsia can be challenging but appropriate management can improve quality of life. 4
Causes
Dyspepsia is a symptom and not a diagnosis. Possible underlying diagnoses causing dyspepsia include organic gastrointestinal diseases such as peptic ulcer disease, GORD, and much less commonly malignancy. However, functional dyspepsia (also Recommended management of dyspepsia in primary care
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Dyspepsia is a symptom frequently encountered in primary care, and is associated with poor health-related quality of life. This article discusses the causes of dyspepsia, the investigations required and current treatment approaches. H. pylori is strongly associated with peptic ulcer disease and weakly associated with functional dyspepsia. NSAIDs can cause symptoms through gastro-duodenal inflammation/ulceration but can also cause dyspepsia in the absence of mucosal injury. Endoscopic findings in patients with dyspepsia are shown in Figure 1 . 5 There are several other gastrointestinal and non-gastrointestinal diagnoses of upper abdominal pain, which may also cause dyspepsia; these are listed in Table 1 .
Investigation and management
The overall management of dyspepsia has not changed significantly since the NICE guideline was published in 2014. 1 At first presentation, patients should be assessed for alarm symptoms, which are summarised in Table 2 . The presence of any of these symptoms should prompt urgent referral for endoscopic examination. NICE guidance adopts a practical approach and differentiates between uninvestigated and investigated dyspepsia.
Management of uninvestigated dyspepsia
This primarily applies to the group of patients without any alarm symptoms. In the absence of alarm symptoms, NICE continues to promote an empirical strategy of managing dyspepsia without endoscopic investigation. Figure 2 shows a useful flowchart for the management of uninvestigated dyspepsia based on the NICE guideline. Current guidance suggests that symptomatic patients should be offered full-dose proton pump inhibitor (PPI) therapy for one month and if symptoms are ongoing, should then be tested for H. pylori infection and treated with eradication therapy if positive. In persistently refractory cases, a trial of a prokinetic agent can be considered if postprandial fullness and early satiation are key features. Management for IBS should be considered if symptoms of altered bowel habit and abdominal pain dominate. It is also important to bear in mind psychological diagnoses, and consider the use of antidepressants and referral for psychological therapy. However, referral to secondary care for further assessment is also appropriate.
Management of investigated dyspepsia
In GORD, full-dose PPI therapy should be given for one to two months. In severe oesophagitis, full-dose PPIs should be given for two months followed by repeat endoscopy to assess healing. Peptic ulcer disease requires testing and treatment for H. pylori. Gastric ulcers require repeat endoscopy after six to eight weeks of full-dose PPI, to ensure the gastric ulcer has healed and is not malignant. Duodenal ulcers do not need follow-up endoscopy since malignant change is extremely rare. Investigated patients with normal endoscopic findings often have functional dyspepsia and should be managed as per the uninvestigated dyspepsia pathway. However, normal endoscopic findings can be found in some dyspeptic patients who have non-erosive gastro-oesophageal reflux.
Treatment of dyspepsia
As indicated above, treatment of dyspepsia will be dependent on whether a patient has been investigated or not, and the findings (or lack of) in a patient who has been investigated. Dyspepsia secondary to an organic cause found at endoscopy should be treated according to the findings. Lifestyle advice should be offered, with NICE recommending smoking cessation, reduction in alcohol consumption, healthy eating and weight reduction.
PPIs remain the main pharmacological intervention in the management of dyspepsia. Other drugs commonly used include Table 2 . Criteria for urgent endoscopy for suspected cancer, to be completed within two weeks of referral received H 2 -receptor antagonists and prokinetics. These medications have been shown to be more effective than placebo. 6 PPIs have shown superiority over H 2 -receptor antagonists due to their ability to maintain intragastric pH >4 for longer periods of time. 7 There are several PPIs available. Their mechanism of action, ie blocking the parietal cell gastric acid pump, is essentially the same; however, PPIs vary in the degree of acid suppression as well as the speed of onset of acid inhibition. 8 It is important that patients use PPIs correctly in order to maximise their benefits. Gastric parietal cells are stimulated to secrete acid post-prandially. Therefore, patients should take PPIs 30-60 minutes before their first meal of the day. It can be useful to split the PPI dose, with the second dose taken before the evening meal.
In patients who have been on PPIs for six months or longer, rebound acid hypersecretion can occur on sudden withdrawal. These patients should therefore follow a tapering regimen to prevent recurrence of symptoms. The dose can be reduced by 50% every week. Once on the lowest dose for one week, the patient can be instructed to take the medication on an as-needed basis or stop altogether. 9 
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Helicobacter pylori eradication regimens
The main update to the most recent NICE guideline is with regard to the H. pylori eradication regimens in primary care, and the latest version reflects the new restrictions on the use of fluoroquinolone antibiotics. Tables 3 and 4 outline the current advice. Referral to a gastroenterologist is advised if second-line treatment fails.
New approaches in functional dyspepsia
The management of functional (also referred to as non-ulcer) dyspepsia is an ongoing challenge in primary care. Acid suppression with PPIs or H 2 -receptor antagonists remains the initial strategy, but it is often ineffective. H. pylori eradication therapy can benefit patients with functional dyspepsia who have this infection. However, the number needed to treat is 15. 10 Novel pharmacological therapies continue to be evaluated. The response rate to placebo in functional dyspepsia trials is 30-40%. 11 Prokinetic drugs are superior to placebo in functional dyspepsia. 12 Metoclopramide and domperidone are both prokinetic drugs available in the UK. The novel prokinetic drug acotiamide is an acetylcholinesterase inhibitor that accelerates gastric emptying and enhances gastric accommodation. 10 The efficacy of acotiamide has been demonstrated, and it is used in Japan for the treatment of functional dyspepsia. 13 Phase 3 trials are still ongoing in Western populations. Further research is also required for buspirone and tandospirone; both drugs act on the 5-HT 1A receptor leading to gastric fundus relaxation. 11 Further research has continued to support a role for tricyclic antidepressants such as amitriptyline in the treatment of functional dyspepsia. 14, 15 A small randomised placebo-controlled study has also shown promise for the atypical antidepressant mirtazapine. 16 Psychotherapy is considered as a potential treatment option in the 2014 NICE guideline, and may reduce symptoms in the short term. Evidence shows that patients with anxiety have an increased risk of developing functional dyspepsia. 17 A Spanish study that compared conventional medical therapy to conventional medical therapy plus psychotherapy showed that the latter treatment group had a significant improvement in symptoms. 18 However, it was not deemed to be a cost-effective treatment strategy and so has not been recommended as routine practice.
Some studies have suggested that acupuncture may be of benefit to patients with functional dyspepsia. 19 However, these are small studies with a high risk of bias. Further studies need to be carried out in order to exclude the placebo effect.
Conclusion
Dyspepsia continues to be a highly prevalent symptom in primary care. It is helpful to distinguish between investigated and uninvestigated dyspepsia when deciding on treatment. PPIs continue to be the mainstay of therapy; however, lifestyle advice and other therapies can also be beneficial. New approaches and therapies for functional dyspepsia continue to be evaluated, and some suggest promise for the future.
PPI Dose
Esomeprazole Lansoprazole Omeprazole Pantoprazole Rabeprazole 20mg 30mg 20-40mg 40mg 20mg Table 3 . NICE-recommended proton pump inhibitor (PPI) doses for the eradication of Helicobacter pylori 1
First-line treatment
Seven-day twice daily course of treatment with:
People who test positive for H. pylori
• A PPI (see Table 3 ) and
• Amoxicillin and • Either clarithromycin or metronidazole, depending on recent exposure
Patients with penicillin allergy
• Clarithromycin and • Metronidazole
Patients with penicillin allergy and previous exposure to clarithromycin
• Bismuth and • Metronidazole and • Tetracycline
Second-line treatment Seven-day twice daily course of treatment with:
People who still have symptoms after first-line eradication treatment
• A PPI (see Table 3 ) and • Amoxicillin and • Either clarithromycin or metronidazole (whichever was not used initially)
Patients with previous exposure to clarithromycin and metronidazole
• A PPI (see Table 3 
